Imbria Secures $57.5M in Series B to Power Breakthrough Cardiometabolic Therapies

Imbria, a pioneering clinical-stage company dedicated to developing novel therapies for patients with life-altering cardiometabolic disorders, has proudly announced the successful closing of its latest funding round, raising an impressive $57,500,000. This significant infusion of capital underscores investor confidence in Imbria’s innovative approach to addressing cardiovascular conditions by restoring or improving the cell’s ability to produce energy—a critical factor in many debilitating heart disorders. The company’s mission is clear: to transform the lives of patients grappling with conditions where energetic impairment is a fundamental contributor to symptoms and functional deficits. At the forefront of Imbria’s clinical portfolio is its lead product candidate, ninerafaxstat, which is currently in Phase 2 clinical development. Ninerafaxstat is being evaluated across three key indications, including nHCM, stable angina, and HFpEF, highlighting the potential broad impact of the therapy in the realm of cardiovascular health. The funds raised will be strategically deployed to accelerate the ongoing clinical trials, expand research and development initiatives, and further enhance the company’s scientific capabilities. This additional capital will empower Imbria to advance its clinical-stage pipeline more rapidly and robustly, ensuring that promising therapeutic breakthroughs reach patients in need as efficiently as possible. By dedicating resources to both clinical advancement and underlying research, Imbria is well-positioned to address the unmet needs in the treatment of cardiometabolic disorders. The company’s vision of harnessing cellular energy pathways to alleviate disease symptoms represents a new frontier in cardiovascular medicine. For those interested in learning more about Imbria’s milestones and ongoing developments, additional information can be found on their website at www.imbria.com.